BPC-157 Oral Capsules

Description

BPC-157 Oral Capsules offer the extensively studied Body Protection Compound-157 peptide in a convenient gastric-resistant capsule format designed specifically for oral route bioavailability research. While BPC-157 is traditionally supplied as a lyophilized powder for reconstitution, the oral capsule formulation addresses a growing area of scientific interest: the study of peptide stability and absorption through the gastrointestinal tract. Each bottle contains 60 capsules, providing researchers with sufficient material for extended oral administration protocols.

One of the defining characteristics of BPC-157 that makes it uniquely suited for oral delivery research is its inherent gastric stability. Unlike most peptides, which are rapidly degraded by stomach acid and digestive enzymes, BPC-157 is derived from a protein naturally present in human gastric juice and has demonstrated remarkable resistance to enzymatic hydrolysis in gastric conditions. Studies using simulated gastric fluid have shown that BPC-157 retains its structural integrity at pH levels as low as 1.5, conditions that would destroy most other peptide molecules within minutes. This stability profile is attributed to the peptide's proline-rich sequence, which confers resistance to cleavage by pepsin and other gastric proteases.

The capsules utilize a gastric-resistant (enteric-coated) shell designed to survive the acidic stomach environment and dissolve in the higher pH conditions of the small intestine. While BPC-157 itself demonstrates gastric stability, the enteric coating provides an additional layer of protection and ensures consistent release in the intestinal lumen, where the majority of peptide absorption occurs. This dual-protection approach — inherent peptide stability combined with formulation engineering — represents a methodologically robust approach to oral peptide delivery research.

Preclinical research on oral BPC-157 administration has produced noteworthy results. In rodent models of inflammatory bowel disease, oral BPC-157 treatment was associated with reduced colonic inflammation, accelerated mucosal healing, and improvement in disease activity scores. Gastrointestinal studies have shown that orally administered BPC-157 exerts cytoprotective effects throughout the digestive tract, including protection against NSAID-induced gastric lesions, alcohol-induced mucosal damage, and stress-induced intestinal barrier dysfunction. Researchers have also investigated the systemic effects of oral BPC-157, finding evidence of tissue-protective activity beyond the gastrointestinal tract in animal models.

For laboratories focused on oral peptide pharmacology, these capsules eliminate the reconstitution step and associated sterility concerns inherent in working with lyophilized powders. The pre-measured capsule format also provides improved dosing accuracy for oral administration studies, reducing the variability that can arise from manual preparation of oral solutions. Each capsule contains BPC-157 peptide at research-grade purity exceeding 98% as verified by HPLC analysis, encapsulated under cGMP conditions to ensure batch-to-batch consistency.

Composition

• Active Peptide: BPC-157 (Body Protection Compound-157)
• Format: Gastric-resistant (enteric-coated) capsules
• Capsule Count: 60 capsules per bottle
• BPC-157 Molecular Formula: C62H98N16O22
• BPC-157 Molecular Weight: 1419.53 g/mol
• Purity: >98% (HPLC)
• Excipients: Microcrystalline cellulose, enteric coating (hypromellose phthalate)

Storage

• Store capsules at room temperature (15-25C) in a cool, dry place.
• For extended storage (beyond 6 months), refrigerate at 2-8C.
• Keep bottle tightly sealed when not in use.
• Avoid exposure to excessive heat, humidity, and direct sunlight.
• Shelf life: 18 months from manufacture date when stored properly.

Certificate of Analysis

Every batch of BPC-157 Oral Capsules sold by Pepspan undergoes rigorous third-party testing. Our Certificate of Analysis (COA) includes HPLC purity analysis of the peptide content, mass spectrometry confirmation, dissolution testing to verify enteric coating performance, content uniformity testing across capsule samples, and microbial limit testing. COA documentation is available upon request for any batch number. All testing is performed by independent European laboratories.

Current Batch: Pending first shipment

Every batch of BPC-157 Oral sold by Pepspan is independently tested by Janoshik Analytical (Prague, Czech Republic). HPLC purity analysis, mass spectrometry, and amino acid sequencing are performed for each shipment. Reports are batch-specific — not generic.

Research Disclaimer

This product is intended for laboratory research use only. It is not a drug, food, cosmetic, or dietary supplement. BPC-157 Oral Capsules are not approved for human or veterinary use by any regulatory agency. They must not be administered to humans or animals outside of approved clinical trials. By purchasing this product, you confirm that you are a qualified researcher and that this product will be used exclusively for legitimate scientific research purposes. Pepspan assumes no liability for any misuse of this product. All handling must comply with local regulations and institutional safety protocols.